|
Authors
|
Franiak-Pietryga, I. ; Ziemba, B. ; Sikorska, H. ; Jander, M. ; Kuncman, W. ; Danilewicz, M. ; Appelhans, D. ; Lewkowicz, P. ; Ostrowska, K. ; Bryszewska, M. ; Borowiec, M.
|
|
Title
|
Maltotriose-modified poly(propylene imine) Glycodendrimers as a potential novel platform in the treatment of chronic lymphocytic Leukemia. A proof-of-concept pilot study in the animal model of CLL
|
|
Date
|
03.08.2020
|
|
Number
|
58757
|
|
Abstract
|
Cancer nanotherapeutics have shown promise in resolving some of the limitations of conventional drug delivery systems such as nonspecific biodistribution and targeting, lack of water solubility, and low therapeutic indices, Among the various nanoparticles that are available, dendrimers, highly branched macromolecules with a specific size and shape, are one of the most promising ones. In this preliminary study, we tested the anti-tumor activity of maltotriose-modified fourth-generation poly(propylene imine) glycodendrimers (PPI-G4-M3) in vivo in the subcutaneous MEC-1 xenograft model of human chronic lymphocytic leukemia (CLL) in NOD scid gamma mice. Fludarabine was used for model validation and as a positive treatment control. The anti-tumor response was calculated as tumor volume, tumor control ratio, and tumor growth inhibition. The study showed that PPI-G4-M3 inhibited subcutaneous tumor growth more efficiently than fludarabine. The anti-tumor response was dose-dependent. Cationic PPI-G4-M3 showed the highest anti-tumor activity but also higher toxicity than the neutral dendrimers and fludarabine. These first promising results warrant further studies in the optimization of dendrimers charge, dose, route and schedule of administration to combat CLL.
|
|
Publisher
|
Toxicology and Applied Pharmacology
|
|
Wikidata
|
|
|
Citation
|
Toxicology and Applied Pharmacology 403 (2020) 115139
|
|
DOI
|
https://doi.org/10.1016/J.TAAP.2020.115139
|
|
Tags
|
|
